2007 (30 Publikationen)

  • Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemssen F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U; Tübingen Bevacizumab Study Group. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48: 2814-2823 [IF 3.528]
  • Rohrbach JM, Grüb M, Szurman P. Einseitige, rezidivierende Trübung des Hornhautepithels. Ophthalmologe 2007; 223: 72-74 [IF 0.791]
  • Szurman P, Petermeier K, Grisanti S, Jaissle GB, Bartz-Schmidt KU. A new small-incision technique for injector implantation of transsclerally sutured foldable lenses. Ophthalmic Surg Lasers Imaging 2007; 38: 76-80 [IF 1.432]
  • Lüke M, Krott R, Warga M, Szurman P, Grisanti S, Bartz-Schmidt KU, Schneider T, Lüke C. Effects of the protein tyrosine kinase inhibitor genistein and taurine on retinal function in isolated superfused retina. Graefes Arch Clin Exp Ophthalmol 2007; 245 : 242-248 [IF 1.59]
  • Spitzer MS, Szurman P, Rohrbach JM, Aisenbrey S. Beidseitiges kongenitales Glaukom bei einem Kind mit Cutis marmorata telangiectatica congenita. Klin Monatsbl Augenheilkd 2007; 224: 66-69 [IF 0.576]
  • Gekeler F, Szurman P, Grisanti S, Weiler U, Claus R, Greiner TO, Volker M, Kohler K, Zrenner E, Bartz-Schmidt KU. Compound subretinal prostheses with extra-ocular parts designed for human trials: successful long-term implantation in pigs. Graefes Arch Clin Exp Ophthalmol 2007; 245: 230-241 [IF 1.59]
  • Jaissle GB, Szurman P, Völker M, Bartz-Schmidt KU. Epiretinal deposit of triamcinolone acetonide at the posterior pole after intravitreal injection. Ophthalmic Surg Lasers Imaging 2007; 38: 238-241 [IF 1.432]
  • Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU; Tübingen Bevacizumab Study Group, Schraermeyer U. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007; 143: 995-1002 [IF 2.628]
  • Spitzer MS, Szurman P, Aisenbrey S, Rohrbach JM. Rapid development of band keratopathy of corneal graft after treatment with intracameral recombinant tissue plasminogen activator for postoperative fibrin reaction. Eur J Ophthalmol 2007; 17: 433-436 [IF 1.018]
  • Szurman P, Roters S, Grisanti S, Aisenbrey S, Rohrbach JM, Warga M, Gelisken F, Spitzer MS, Bartz-Schmidt KU. Primary silicone oil endotamponade in the management of severe intraocular foreign body injuries: an eight-year follow-up. Retina 2007; 27: 304-311 [IF 3.088]
  • Szurman P, Kaczmarek R, Jaissle GB, Grisanti S, Lüke M, Spitzer MS, Heide PE, Bartz-Schmidt KU. Influence of different purification techniques on triamcinolone yield and particle size spectrum. Graefes Arch Clin Exp Ophthalmol 2007; 245: 689-696 [IF 1.59]
  • Ziemssen F, Lüke M, Messias A, Beutel J, Tatar O, Zrenner E, Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group. Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol 2007; 28: 101-109 []
  • Petermeier K, Szurman P. Subjektive und objektive Ergebnisse nach Implantation der apodisiert diffraktiven AcrySof ReSTOR. Ophthalmologe 2007; 104: 399-408 [IF 0.791]
  • Tatar O, Adam A, Shinoda K, Yoeruek E, Szurman P, Bopp S, Eckardt C, Bartz-Schmidt KU, Grisanti S. Influence of Verteporfin Photodynamic Therapy on Inflammation in Human Choroidal Neovascular Membranes secondary to Age-Related Macular Degeneration. Retina 2007; 27: 713-723 [IF 3.088]
  • Aisenbrey S, Bartz-Schmidt KU, Walter P, Hilgers RD, Ayertey H, Szurman P, Thumann G. Long-term follow-up of macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration. Arch Ophthalmol 2007; 125: 1367-1372 [IF 2.984]
  • Peters S, Altvater A, Bopp S, Vonthein R, Szurman P, Spitzer MS, Warga M, Lüke M, Bartz-Schmidt KU, Grisanti S. Systematic evaluation of ICG and Trypan Blue related effects on ARPE-19 cells in vitro. Exp Eye Res 2007; 85: 880-889 [IF 2.651]
  • Spitzer MS, Sierra A, Yoeruek E, Wallenfels-Thilo B, Schraermeyer U, Spitzer B, Bartz-Schmidt KU, Szurman P. Comparative antiproliferative and cytotoxic profile of bevacizumab (AvastinTM), pegaptanib (MacugenTM) and ranibizumab (LucentisTM) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 2007 ; 245 : 1837-1842 [IF 1.59]
  • Szurman P, Sierra A, Kaczmarek R, Jaissle GB, Wallenfels-Thilo B, Grisanti S, Lüke M, Bartz-Schmidt KU, Spitzer MS. Different biocompatibility of crystalline triamcinolone deposits on retinal cells in vitro and in vivo. Exp Eye Res 2007, 85: 44-53 [IF 2.651]
  • Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU, Szurman P. Safety profile of bevacizumab (Avastin®) on cultured human corneal cells. Cornea. 2007; 26: 977-982 [IF 1.776]
  • Yoeruek E, Jaegle H, Lüke M, Grisanti S, Warga M, Krott R, Spitzer MS, Tatar O, Bartz-Schmidt KU, Szurman P. Safety profile of a taurine containing irrigation solution (AcriPurRet®) in pars plana vitrectomy. Retina 2007; 27: 1286-1291 [IF 3.088]
  • Aisenbrey S, Ziemssen F, Völcker M, Gelisken F, Szurman P, Jaissle G, Grisanti S, Bartz-Schmidt KU. Intravitreal bevacizumab (Avastin) for occult choroidale neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245: 941-948 [IF 1.59]
  • Jaissle GB, Szurman P, Rohrbach JM, Gelisken F, Bartz-Schmidt KU. A case of cutaneous melanoma metastatic to the vitreous cavity: Possible pathomechanism and review of the literature. Graefes Arch Clin Exp Ophthalmol 2007; 245: 733-740 [IF 1.59]
  • Heiligenhaus A, Szurman P, Heinz C. Aktuelle Kataraktchirurgie bei Uveitis im Kindesalter. Ophthalmologe 2007; 104: 572-576 [IF 0.791]
  • Peters S, Julien S, Heiduschka P, Grisanti S, Ziemssen F, Adler M, Schraermeyer U, Bartz-Schmidt KU; The Tuebingen Bevacizumab Study Group. Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol 2007; 91: 827-831 [IF 2.689]
  • Szurman P, Heiligenhaus A, Hettlich HJ, Dick HB, Kohnen T. Kataraktchirurgie bei Uveitis im Kindesalter. Klin Monatsbl Augenheilkd 2007; 224: 532-537 [IF 0.576]
  • Aisenbrey S, Gelisken F, Szurman P, Bartz-Schmidt KU. Surgical treatment of peripapillary choroidal neovascularization. Br J Ophthalmol 2007; 91: 1027-1030 [IF 2.689]
  • Beutel J, Greulich L, Lueke M, Ziemssen F, Szurman P, Bartz-Schmidt KU, Grisanti S. Inner Limiting Membrane as membranous support in RPE sheet-transplantation. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1469-1473 [IF 1.59]
  • Lüke M, Januschowski K, Warga M, Beutel J, Leitritz M, Gelisken F, Grisanti S, Schneider T, Lüke C, Bartz-Schmidt KU. Szurman P. The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator. Br J Ophthalmol 2007; 91: 1077-1082 [IF 2.689]
  • Gelisken F, Voelker M, Schwabe R, Besch D, Aisenbrey S, Szurman P, Grisanti S, Herzau V, Bartz-Schmidt KU. Full Macular Translocation versus Photodynamic Therapy with Verteporfin in Treatment of Neovascular Age-related Macular Degeneration: 1 Year Results of a prospective, controlled, randomised Pilot-Trial (FMT-PDT). Graefes Arch Clin Exp Ophthalmol 2007, 245: 1085-1095 [IF 1.59]
  • Lüke M, Szurman P, Schneider T, Lüke C. Effects of the phosphodiesterase type V inhibitor sildenafil on human retinal function in vitro. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1211-1215 [IF 1.59]

Kontakt

Callcenter:
06897 / 574-1121

E-Mail-Formular

Notfallambulanz (Pforte, außerhalb der Callcenter-Sprechzeiten):
06897 / 574-0

Privatambulanz (Chefarzt-Sekretariat):
06897 / 574-1119

Adresse:
Augenklinik Sulzbach, An der Klinik 10
66280 Sulzbach

Anfahrt

Kontakt

Logo KHERI augenklinik saar

KTQ Zertifikat

Wussten Sie schon?

Unser hohes Maß an Qualität wurde uns als erster Klinik im Saarland offiziell zertifiziert. Das KTQ-Siegel steht für Patientenorientierung, geprüfte Qualität und Sicherheit.